Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04176679
Other study ID # RECHMPL19_0532
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2013
Est. completion date November 1, 2019

Study information

Verified date November 2019
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

Hypervascularized products of conception remain a topic debated in terms of definitions (ultrasound criteria, need complement by angio MRI) and management. The different uterine vascular lesions are often confused. This is a recurrent problem and care are heterogeneous. The aim of the study is to evaluate the management of these entities in CHU of Montpellier and determine more homogeneous care. The investigators further aimed to evaluate clinical presentation, ultrasound criteria, complications and the gynaecological and obstetrical outcomes of patients •Methods: This study will be conducted in compliance of ethic comitee. The investigators will collect data from 64 individuals, aged 18 to 50, suffering from uterine vascular lesions associated or not with products of conception between 2013 and 2019. Caracterisitics of the population, ultrasound and angio MRI data will be collected. Management wll be described as expectative, surgery or embolization of uterine arteries and the success or not will be noted. The investigators will question patients on their gynaecologic and obstetrical outcomes by telephone.

•Discussion: The investigators aim to define and characterize the different lesions, establish ultrasound criteria that would guide treatments. Describe the current treatments and compare them in terms of efficiency and safety in order to establish a homogeneous treatment protocol in our center


Description:

- data are collected by computer software and patient phone calls

- ultrasounds criteria are reviewed by two clinicians

- statistical analysis is realized by a independent clinician

- the consent and agreement of the ethics committee has been sought


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date November 1, 2019
Est. primary completion date October 1, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion criteria:

- Women

- Aged between 18 and 50 years

- Managed in CHU Montpellier

- Diagnosis of hypervascularized products of conception

- Available ultrasound pictures

Exclusion criteria:

- Subject unable to understand the study

- Subject with another diagnosis of bleeding

- Subject who have retained products of conception with no vascularity or immediate curettage with uterine vacuity

- Subject who have no available ultrasound pictures

Study Design


Related Conditions & MeSH terms

  • Hypervascularized Uterine Retentions

Locations

Country Name City State
France Uh Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evolution of the effects of the selected design products Evolution of the effects of the selected design products the incidence of retained products of conception associated with enhanced myometrial vascularity 1 day
Primary ultrasound vascularity assessment ultrasound vascularity assessment for predicting future severe hemorrhage in retained products of conception with comparison of doppler color score (scale of the author Akiba, Kamaya and the Doppler color scoring system) 1 day
Primary compare managing of these entities compare managing of these entities: expectative, surgery, embolization, hysteroscopy in terms of efficiency (stopping bleeding) and safety 1 day
Secondary assessment of the women quality of life assessment of the women quality of life during managing , future fertility and pregnancy, gynaecologic healing with a telephone survey 1 day